High-altitude heart disease
Conditions
Interventions
Transcriptomics cohort: HAHD patients:None
Transcriptomics cohort: Healthy controls at the same altitude:None
Proteomics cohort: HAHD patients:None
Proteomics cohort: Healthy controls at the same altitude:None
Group 1 (High Altitude Heart Disease group): Control group:Intermittent oxygen therapy
Group 1 (High Altitude Heart Disease group): Intervention Group 1 (Intermittent oxygen therapy + calcium antagonist [amlodipine 5 mg qd]):Intermittent oxygen therapy + calcium antagonist (amlodipine 5
Group 1 (High Altitude Heart Disease group): Intervention Group 2:Intermittent oxygen therapy + targeted drug therapy (phosphodiesterase-5 inhibitor, endothelin receptor antagonist)
Group 2 (High Altitude Heart Disease with Right Heart Failure group): Control group (conventional therapy):Oxygen therapy + basic treatment
Group 2 (High Altitude Heart Disease with Right Heart Failure group): Trial group:Conventional therapy + SGLT2i
Sponsors
Xizang Autonomous Region People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Part 1: Individuals meeting the diagnostic criteria for High Altitude Heart Disease (HAHD); a healthy control group at the same altitude was simultaneously established. All participants were recruited from patients admitted to the Department of Cardiology, Tibet Autonomous Region People’s Hospital, with a residence altitude >= 3500 m and continuous residence for >= 6 months. Part 2: 1. Group 1 (High Altitude Heart Disease group): Met the diagnostic criteria for high altitude heart disease without signs of right heart failure; 2. Group 2 (High Altitude Heart Disease with Right Heart Failure group): Met the diagnostic criteria for high altitude heart disease with concomitant right heart failure (right atrial pressure RAP >= 15 mmHg, cardiac index < 2.0 L·min^-1·m^-2)
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptomic and proteomic data;Event-Free Survival (EFS);Functional Improvement: Improvement in NYHA Functional Class by =1 grade;Exercise Tolerance: Improvement in Six-Minute Walk Distance by =50 meters; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemodynamic Improvement: Reduction in Right Atrial Pressure, Pulmonary Artery Pressure, and Improvement in Cardiac Index;Biomarkers: Changes in BNP and NT-proBNP Levels;Quality of Life: Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score;Hospitalization Rate; | — |
Countries
China
Contacts
Public ContactKelsang Norbu
Xizang Autonomous Region People's Hospital
Outcome results
None listed